We describe a 41-year-old man with a 1-week history of nausea and vomiting 1 month after chemoembolization of a liver metastasis. The patient subsequently became febrile and developed right upper quadrant abdominal and midback pain. Findings of initial laboratory and imaging studies (a noncontrast computed tomographic [CT] scan and ultrasound) were not remarkable. Hepatobiliary scintigraphy, performed to rule out cholecystitis, revealed an abnormal area in the right lobe of the liver consistent with a focal bile leak into an abscess cavity. The patient was subsequently treated for liver abscess. In conclusion, hepatobiliary scintigraphy should be considered as a first-line test in the work-up of patients whenever a postchemoembolization complication is considered likely.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00003072-200203000-00006DOI Listing

Publication Analysis

Top Keywords

hepatobiliary scintigraphy
12
liver abscess
8
patient subsequently
8
postchemoembolization liver
4
abscess findings
4
findings hepatobiliary
4
scintigraphy describe
4
describe 41-year-old
4
41-year-old man
4
man 1-week
4

Similar Publications

Hepatocellular carcinoma (HCC) and biliary tract cancers (BTC) pose significant diagnostic and therapeutic challenges. Magnetic resonance imaging (MRI) and multiphase computed tomography (CT) have been the preferred imaging modalities for diagnosis, staging, and surveillance of patients with these malignancies. The best clinical outcomes depend on the appropriate selection of treatment options from the tools available in neo-adjuvant therapy, surgical resection, locoregional therapy, liver transplantation, and adjuvant therapy.

View Article and Find Full Text PDF

Validation of an alternative two-strip method for the quality control of [Tc]Tc-ETIFENIN (TECHIDA®).

Appl Radiat Isot

March 2025

Radiopharmacy Unit, Department of Pharmacy, Groupement Hospitalier Sud - Hospices Civils de Lyon, 165 chemin du Grand Revoyet, 69495, Pierre-Bénite, France; Department of Pharmacy - Groupement Hospitalier Sud - Hospices Civils de Lyon, 165 chemin du Grand Revoyet, 69495, Pierre-Bénite, France.

For hepatobiliary scintigraphy, the radiopharmaceutical drug, ETIFENIN (TECHIDA®), labelled with technetium-99m, is used as a substitute for MEBROFENIN (CHOLEDIAM®). It is generally accepted that radiopharmaceuticals should be checked prior to injection, in particular by determining radiochemical purity, to ensure high-quality images. Radiochromatographic techniques or methods described in the Summary of Product Characteristics (SmPC) and the European Pharmacopeia (Ph.

View Article and Find Full Text PDF

Background: To study the feasibility of hepatobiliary scintigraphy (HBS) to improve selection and planning of patients with hepatocellular carcinoma (HCC) treated with holmium-166 (Ho)-microspheres radioembolization.

Results: Thirty-one patients with HCC were included and treated with Ho- radioembolization as part of a prospective phase 2 study. Twenty-seven patients were eligible for analysis, 67% had a cirrhotic liver morphology on imaging, 70% had multifocal disease and 51% had bilobar disease.

View Article and Find Full Text PDF

Background Gallstone disease significantly burdens the United States healthcare system. While ultrasonography (US), physical exam, and laboratory findings are the recommended primary workup and diagnostic modalities, hepatobiliary scintigraphy (HIDA) scans are occasionally used as an adjunct for diagnosis. This study evaluates HIDA scan utilization in comparison to clinical and US findings based on the Tokyo guidelines for diagnosing acute cholecystitis.

View Article and Find Full Text PDF

PET/MRI evaluation of hepatobiliary tumors.

Q J Nucl Med Mol Imaging

December 2024

Department of Radiology, UT Southwestern Medical Center, Dallas, TX, USA -

Positron-emission tomography magnetic resonance imaging (PET/MRI) has emerged as a powerful hybrid molecular imaging technique in clinical practice, overcoming initial technical challenges to provide comprehensive anatomic and metabolic information. This advanced modality combines the superior soft tissue contrast of MRI with the metabolic insights of PET, offering advantages in hepatobiliary imaging, including improved detection of small liver metastases and reduced radiation exposure. The evolution of PET/MRI technology has been marked by significant advancements, such as the development of MRI-compatible PET detectors and sophisticated motion compensation techniques.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!